Current Issues in the Management of Patients With HCV and Chronic Kidney Disease
A CME-certified Symposium



Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements below.


Registration

  VenueCityStateDate
View Agenda  Omni Nashville Hotel
Broadway K Ballroom
NashvilleTN Sunday
Mar 19, 2017 6:30 AM


This symposium is approved by the RPA. It is NOT part of the official RPA Annual Meeting as planned by the RPA Program Committee.
 

Presentation Slides

Click here to view the presentation slides from this CME-certified symposium. (coming soon)

Download (PDF) Click here to view the presentation slides from this CME-certified symposium.

Program Description

Hepatitis C virus (HCV) causes chronic renal disease and places patients at increased risk of complications and death. The nephrology team has an important role to play in HCV patient management. This CME-certified satellite symposium will inform renal physicians and dialysis directors about HCV management in patients with chronic kidney diseases, including the importance of early diagnosis and treatment, as well as issues related to pre- and post-transplant status.

Agenda


Welcome and Introductions
Impact of HCV and Available Treatment Options for Patients with Kidney Disease
Approach to Treatment in Kidney Transplant Candidates
Closing Remarks and Q&A


Target Audience

This activity is intended for attendees of the Renal Physicians Association Annual Meeting and other clinicians who care for patients with renal impairment and HCV.


Educational Objectives


At the conclusion of this activity, participants should be able to demonstrate the ability to:
  • Summarize the impact of HCV infection as both a cause of kidney disease and a contributor to its progression into ESRD
  • Summarize available evidence and clinical trial data on the impact of direct-acting antivirals to treat HCV in patients with kidney disease and patients on dialysis
  • Review strategies to minimize transmission and eradicate HCV in patients with kidney disease and ESRD
  • Discuss issues relevant to the HCV-infected kidney transplant candidate and recipient including the option to use HCV-positive donors and how that impacts on the timing for treatment of the recipient

Program Faculty

Roy D. Bloom, MD
Professor of Medicine
University of Pennsylvania Perelman School of Medicine
Medical Director, Kidney Transplant Program
Penn Transplant Institute
Philadelphia, PA

 

David Roth, MD
William W. Anderson Professor of Nephrology
University of Miami Miller School of Medicine
Miami, FL 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email contact@potomacme.org.

Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.


FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided after submission of a completed evaluation form.

There is no fee associated with this program.

SPECIAL SERVICES

Event staff will be glad to assist you with any specials needs. Please email specialservices@rockpointe-pcme.com at least 5 days prior to the program.

PROVIDED BY


Jointly provided by the Potomac Center for Medical Education and Rockpointe

     
     

     


SUPPORTED BY


This program is supported by an educational grant from Merck.

 


Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.

Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.



Registration

  VenueCityStateDate
View Agenda  Omni Nashville Hotel
Broadway K Ballroom
NashvilleTN Sunday
Mar 19, 2017 6:30 AM